Phase 3 testing begins on drug that could prevent COVID-19 infection
DETROIT Medical experts have been using coronavirus antibodies in the form of convalescent plasma to help patients fighting COVID-19, but new research could take that concept to the next level. RELATED: Evrod Cassimy donates plasma, coronavirus antibodies to help othersThe idea is creative a drug that would not only treat those infected with coronavirus, but potentially help prevent infections too. According to biotechnology company Regeneron Pharmaceuticals, phase three clincal trials are now in the works for REGN-COV2, their combination antibody treatment for COVID-19. The drug is a combination of two antibodies -- the proteins the body makes to naturally fight infections. Regeneron was awarded a $450 million contract to manufacture and supply the antibody treatment as part of the federal governments push to get a vaccine by January 2021.